Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | CASP3 | P42574 | 6/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | CASP9 | P55211 | 1/20 | 0.62 |
| ▸ | TGM2 | P21980 | 5/20 | 0.53 |
| ▸ | CES1 | P23141 | 3/20 | 0.53 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL7085293 | 0.98 | CA12 (0.65) | CA12CA1CA2CA9CASP3 | |
| SCHEMBL458636 | 0.98 | CA12 (0.69) | CA12CA1CA2CA9CASP3 | |
| Hydrochloric Acid SCHEMBL5184450 | 0.96 | CA12 (0.67) | CA12CA1CA2CA9CASP3 | |
| SCHEMBL5858448 | 0.96 | CA12 (0.67) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL3652418 | 0.86 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL3680504 | 0.86 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL186296 | 0.86 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL3960977 | 0.84 | CA12 (0.47) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL5455215 | 0.84 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL2732840 | 0.84 | CA12 (0.50) | CA12CA1CA2CA9CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8674006-B2 | Black pigment dispersion | BASF SE Ludwigshafen (DE) | 2014-03-18 | — | — | US | disclosed |
| US-8623906-B2 | Carboxy isatin hydrazones and their esters as Shp2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2387599-B1 | BLACK PIGMENT DISPERSION | BASF SE (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2240175-B1 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | US GOV HEALTH & HUMAN SERV (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120172498-A1 | BLACK PIGMENT DISPERSION | BASF SE (DE) | 2012-07-05 | — | — | US | disclosed |
| WO-2012033601-A1 | THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110294385-A1 | ORGANIC BLACK PIGMENTS AND THEIR PREPARATION | BASF SE (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-2387599-A1 | BLACK PIGMENT DISPERSION | BASF SE (DE) | 2011-11-23 | — | — | EP | disclosed |
| EP-1335901-B1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | MERCK SERONO SA (CH) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009102433-A2 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| WO-2007117699-A2 | INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-10-18 | — | — | WO | disclosed |
| US-6902861-B2 | Infrared absorbing compounds and their use in photoimageable elements | KODAK POLYCHROME GRAPHICS, LLC (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040180285-A1 | Infra red absorbing compounds and their use in photoimageable elements | LASER PACIFIC MEDIA CORPORATION | 2004-09-16 | — | — | US | disclosed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | disclosed |
| EP-1335901-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | PTPN7, PTPN1, PTPN2 | CA12 4218/4885CA1 4364/4885CA2 3177/4885 |
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | PTPN1, PTPN2, PTPN7 | CA12 3790/4885CA1 3818/4885CA2 2138/4885 |
| US-20120172498-A1 | BLACK PIGMENT DISPERSION | NDUFB1, NDUFA1, NDUFB11 | CA12 4659/4885CA1 4865/4885CA2 4706/4885 |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | OXTR, AVPR2, OPRL1 | CA12 3730/4885CA1 4063/4885CA2 2394/4885 |
| US-20110294385-A1 | ORGANIC BLACK PIGMENTS AND THEIR PREPARATION | IK, CRY1, PAH | CA12 4531/4885CA1 4471/4885CA2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.